Compounds, such as tamoxifen, which selectively bind to ER-α, thus, provide an important strategy for the treatment of breast cancer (see Reference [168] for a review of the use of ER-α antagonists in breast cancer). This evidence concerns the gene ESR1 and breast carcinoma.